slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 4,981-5,010
Pages 350
Rows per page 30
Slide type
4,981-5,010 of 10,471
19
Includes statistical significance markers and clinical guideline thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
20
Includes statistical significance (p-values) and MCID reference lines for GMFM-E.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
21
The slide uses a heatmap to visualize individual patient outcomes, a common technique in clinical trial reporting.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
25
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact and Next Steps1 hit
30
Includes histological images of liver tissue and a dot plot showing BMD improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a box plot to visualize longitudinal clinical trial data.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
34
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
35
Includes a study design timeline and clinical endpoint data tables/charts.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
38
The table highlights specific clinical improvements for six individual patients, emphasizing normalization of mobility.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
The slide uses a survey by BCG to validate brand strength and identify a specific operational bottleneck (inventory availability).Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
04
Includes a call-to-action footer for financial results.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
05
The slide uses a 3x3 grid layout of icons paired with quantitative metrics and descriptive text.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
22
The slide highlights the scale of the origination platform and its ability to generate recurring assets.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Solution1 hit
23
The chart shows historical growth from 2020 to 2022 and a 2026 target.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Solution1 hit
29
The chart highlights specific transaction events (Jackson, JCPenney, Lockheed Martin) and market conditions (COVID-19, UK LDI Turmoil) to demonstrate resilience and opportunistic growth.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
35
The chart uses a combination of a line chart for policyholder withdrawals and a bar chart for contractual withdrawals to show historical trends.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
42
The table uses visual indicators (checkmarks and arrows) to denote performance relative to targets.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
12
The slide displays longitudinal data for cohorts E, F, I, J, G, and K, highlighting individual patient responses and key clinical outcomes.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide displays 8 individual patient case studies (Pt 46, 51, 52, 53, 56, 58, 59, 60, 61).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
21
Includes IC50 value and IFN-y fold increase data from patient samples.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
Includes both longitudinal efficacy data (line chart) and pharmacokinetic data (bar charts) comparing plasma vs liver concentrations.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
Includes a quote from Keith Nuechterlein and specific Cohen's d effect size metrics.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Problem1 hit
11
The slide uses a dual-panel layout to compare animal model data (left) with human Phase 1 clinical trial data (right).ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
12
The slide highlights that low doses (40 or 80 mg TID) of RL-007 show superior cognitive performance compared to higher doses and Pregabalin.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
16
The slide uses a line chart to show MADRS score changes over 12 weeks, highlighting the 25mg dose efficacy.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
The slide uses topographical brain maps to visualize EEG data changes.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
25
The chart uses error bars and statistical significance markers (asterisks) to compare dose groups against a zero baseline.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
29
The slide uses a line chart to demonstrate reduction in HCQN subscales over time, and a process diagram to outline the ongoing Phase 1/2 trial stages.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
06
The slide uses a hub-and-spoke style layout to categorize metrics into Customers and Partners, with a background map indicating global reach.Azerion | Investor Presentation Deck | 30 slides · Azerion
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit